This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yun, Y.-S. Articles by Ting, C.-C. Search for Related Content PubMed PubMed Citation Articles by Yun, Y.-S. Articles by Ting, C.-C.

In Vivo Antitumor Activity of Anti-CD3-induced Activated Killer Cells

Office of the Director, Division of Cancer Biology and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892

This study investigates the potential of the CD3-induced killer cells for use in adoptive immunotherapy of tumor growth. The CD3-induced, activated, killer cells (CD3-AK) were generated in DBA/2 (H-2^d) splenocytes by preactivation with CD3 and were then cultured in the presence (CD3-AK [CD³⁺]) or absence (CD3-AK [CD3^-]) of CD3. The conventional lymphokine-activated killer (LAK) cells were induced by culturing DBA/2 splenocytes with purified human recombinant interleukin 2. Testing their in vitro cytotoxicity against syngeneic mastocytoma P815, CD3-AK (CD3⁺) cells gave the highest levels of cytotoxicity and were 20-fold higher than LAK cells and 200-fold higher than CD3-AK (CD3^-) cells. However, the cytotoxic activity of LAK or CD3-AK (CD3^-) cells was augmented by preincubating them with CD3 for 3 h; then, the difference in cytotoxic activity was reduced from 20- to 4-fold and from 200- to 2-fold, respectively. The in vivo antitumor activity of these killer cells paralleled the in vitro activity. In tests using tumor neutralization experiments, 80–100% of the mice that were challenged with 1 x 10² P815 cells remained tumor free after receiving 5 x 10⁶ CD3-AK (CD3⁺) cells. When the challenge dose increased to 1 x 10³ and to 1 x 10⁴ cells, giving CD3-AK (CD3⁺) cells slowed down the rate of tumor growth but only 20% of the mice remained tumor free. The untreated LAK cells or CD3-AK (CD3^-) cells did not induce any protection. After preincubation with CD3 for 3 h, the CD3-AK (CD3^-) cells provided protection in 30% of the challenged mice. The phenotype of effectors for mediating the in vitro and in vivo antitumor activities was found to be Thy1⁺, CD4^-, and CD8⁺ cells. Flow microfluorometry analysis showed that the higher levels of cytotoxic activity obtained with CD3-AK (CD3⁺) cells could not be simply explained by the increase of CD8⁺ cells, and the cytotoxic activity of individual CD3-AK (CD3⁺) cells appeared to be much higher than that of the LAK cells. After tumor growth was established for 1–2 days, giving CD3-AK (CD3⁺) cells slowed down the rate of tumor growth, and 20% of the mice remained tumor free. These results indicate that CD3-AK cells may be used in the immunotherapy of tumor growth. Major advantages of using CD3-AK cells are their high levels of antitumor activity and their fast growth in vitro; they can be expanded to a 10,000- to 100,000-fold increase in cell numbers in 2–3 weeks. Therefore, it appears that CD3-AK may be an ideal candidate for use in the adjuvant immunotherapy of tumor growth.

¹ To whom requests for reprints should be addressed, at Building 10, Room 4B17, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Received 12/12/88. Revised 3/31/89. Revised 5/10/89. Accepted 5/30/89.

This article has been cited by other articles:

				L.-X. Wang, B.-G. Chen, and G. E. Plautz Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion J. Immunol., September 15, 2002; 169(6): 3314 - 3320. [Abstract] [Full Text] [PDF]

				J. Baker, M. R. Verneris, M. Ito, J. A. Shizuru, and R. S. Negrin Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon {gamma} production Blood, May 15, 2001; 97(10): 2923 - 2931. [Abstract] [Full Text] [PDF]

				M. L. Saxton, D. L. Longo, H. E. Wetzel, H. Tribble, W. G. Alvord, L. W. Kwak, A. S. Leonard, C. D. Ullmann, B. D. Curti, and A. C. Ochoa Adoptive Transfer of Anti-CD3-Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity Blood, April 1, 1997; 89(7): 2529 - 2536. [Abstract] [Full Text] [PDF]